Abiraterone metabolite 1

Cat. No.:	HY-103687			
CAS No.:	1940176-03-3			
Molecular Formula:	C ₂₄ H ₃₃ NO			
Molecular Weight:	351.52			
Target:	Drug Metabolite			
Pathway:	Metabolic Enzyme/Protease			
Storage:	Powder	-20°C	3 years	
		4°C	2 years	
	In solvent	-80°C	2 years	
		-20°C	1 year	

SOLVENT & SOLUBILITY

In Vitro	DMSO : ≥ 25 mg/mL (71.12 mM) * "≥" means soluble, but saturation unknown.					
Pre Sto	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	
		1 mM	2.8448 mL	14.2239 mL	28.4479 mL	
		5 mM	0.5690 mL	2.8448 mL	5.6896 mL	
		10 mM	0.2845 mL	1.4224 mL	2.8448 mL	
	Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (7.11 mM); Suspended solution; Need ultrasonic					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (7.11 mM); Clear solution					
	3. Add each solvent o Solubility: ≥ 2.5 mg	one by one: 10% DMSO >> 90% cor g/mL (7.11 mM); Clear solution	n oil			

BIOLOGICAL ACTIVITY)

Description	Abiraterone metabolite 1 is a 5β-reduced metabolite of abiraterone. Abiraterone, a steroidal agent, inhibits CYP17A1, blocks
	androgen synthesis and prolongs survival in prostate cancer.

REFERENCES

Product Data Sheet

Ĥ

Ĥ

HO

Ĥ

N=



[1]. Li Z, et al. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature. 2016 May 26;533(7604):547-51.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA